Featured Research

from universities, journals, and other organizations

Health gains from multiple sclerosis drugs come at a high price, study finds

Date:
July 21, 2011
Source:
University of Rochester Medical Center
Summary:
A new study shows that the health gains associated with a category of medications commonly used to treat multiple sclerosis (MS) -- know as disease modifying drugs -- come at a very high cost when compared to therapies that address the symptoms of MS and treatments for other chronic diseases.

A new study shows that the health gains associated with a category of medications commonly used to treat Multiple Sclerosis (MS) -- know as disease modifying drugs -- come at a very high cost when compared to therapies that address the symptoms of MS and treatments for other chronic diseases.

The study -- which appears in the journal Neurology -- analyzed data from 844 individuals with early stage MS and projected health care costs, including the cost of the drugs, and lost productivity over a 10 year period. The study found that while MS patients using disease- modifying drugs experience modest health gains, the cost associated with using these drugs is more than 8 times higher than what is considered "reasonable" from a health economics cost-effectiveness perspective.

"While it is clear that disease-modifying drugs are beneficial to some MS patients, those gains come at a tremendous economic cost," said Katia Noyes, Ph.D., M.P.H., associate professor in the Department of Community and Preventive Medicine at the University of Rochester Medical Center and lead author of the study. "These results point to the need to continually evaluate the cost-effectiveness of new treatments in the interest of controlling health care costs."

MS is a disease of the central nervous system and is the most common cause of neurological disability in young adults. The disease causes muscle weakness, numbness or tingling in arms and legs, difficulty with coordination, balance and walking, blurred vision, and slurred speech. Early in the course of the disease the symptoms manifest themselves in cycles of acute symptoms followed by periods of remission and recovery. Over time these symptoms tend to become more permanent and debilitating.

In the 1990's several new drugs were introduced that modified the course of the disease, as opposed to traditional therapies that primarily treat the symptoms of MS. These drugs -- which include interferons and glatiramer acetate -- have been shown in large clinical studies to slow the progression of the disease and reduce relapses. However, these drugs are associated with side effects and are very expensive, costing as much as $30,000 per year.

The authors used data from an ongoing survey of MS patients funded by the National Multiple Sclerosis Society. Using this and several other sets of data, it projected the health care costs -- medications, hospital admissions, out-patient visits, diagnostic testing, and home and long term care -- over a 10 year period associated with individuals taking disease-modifying drugs and those who instead underwent other basic treatments to control their symptoms. Health care costs were generated using Medicaid and Medicare reimbursement rates. The study also calculated lost productivity -- interruptions in work or schooling -- and estimated these costs using Bureau of Labor Statistics data.

Noyes and her colleagues employed a method called quality-adjusted life years (QALY) to evaluate the health effects of the drugs. QALY is a standard tool used to evaluate disease burden by estimating the improved quality of life gained over time by taking a particular medication or course of therapy. A general rule of thumb among health policy experts is that for an intervention to be judged "cost-effective" it should cost $100,000 or less to produce an extra QALY. According to the study, disease-modifying drugs for MS cost more than $800,000 per QALY.

Individuals taking disease-modifying drugs experienced a modest improvement in health according to the study. For example, MS patients taking interferon beta-1a gained about 2 quality-adjusted months over 10 years compared to those who did not take disease modifying drugs. Patients taking interferon beta-1b had an average of 6 out of 10 free of relapses compared to 5 years for those not taking the drugs. The authors also found that the benefit to patients was greater if they began taking the drugs early during the onset of the disease.

The study's authors point out that in countries such as Britain, Canada, and Germany the cost of these drugs is 67 percent lower than the U.S. "If we could bring the cost of these drugs in line with what pharmaceutical companies are paid in other industrialized countries, we could significantly improve the cost-benefit ratio," said Noyes.

The study's co-authors include Robert Holloway, M.D., M.P.H., Steven Schwid, M.D. (deceased), and Alina Bajorska, M.S. with URMC, Lahar Mehta M.D. with Evergreen Neuroscience Institute, Bianca Weinstock-Guttman, M.D. with the University at Buffalo, and Andrew Dick, Ph.D. with the Rand Corporation. The study was funding with support from the National Center for Research Resources and the National Multiple Sclerosis Society.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. Noyes, A. Bajorska, A. Chappel, S. R. Schwid, L. R. Mehta, B. Weinstock-Guttman, R. G. Holloway, A. W. Dick. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. Neurology, 2011; DOI: 10.1212/WNL.0b013e3182270402

Cite This Page:

University of Rochester Medical Center. "Health gains from multiple sclerosis drugs come at a high price, study finds." ScienceDaily. ScienceDaily, 21 July 2011. <www.sciencedaily.com/releases/2011/07/110720162039.htm>.
University of Rochester Medical Center. (2011, July 21). Health gains from multiple sclerosis drugs come at a high price, study finds. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/07/110720162039.htm
University of Rochester Medical Center. "Health gains from multiple sclerosis drugs come at a high price, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/07/110720162039.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins